Stephen Kaldor, Ph.D. has served on our board of directors since October 2015. Dr. Kaldor has over 25 years of experience in the biotech and pharmaceutical industries. He currently serves as a director and Chief Executive Officer of Fount Therapeutics, LLC. Dr. Kaldor previously served as President and Chief Executive Officer at Quanticel Pharmaceuticals Inc., from February 2011 until its acquisition by Celgene Corporation in October 2015. Dr. Kaldor was also a venture partner at Versant Ventures from January 2011 until October 2015. Prior to that, Dr. Kaldor served as President and Chief Executive Officer of Ambrx Inc., a biotechnology company. from July 2007 to June 2010. He was the President and Chief Scientific Officer at Syrrx Inc., from March 2003 until its acquisition by Takeda San Diego, Inc., in March 2005, and he continued on as President and Chief Scientific Officer until July 2007.
Dr. Kaldor has served on the board of directors of Resolute Therapeutics, Inc., since October 2016, as a strategic advisor to FronThera US Pharmaceuticals LLC, since March 2016 and as a scientific advisory board member of Crown Bioscience, Inc., since January 2009. Previously, Dr. Kaldor served as a director of Furiex Pharmaceuticals, Inc., from November 2010 until its acquisition by Forest Laboratories, Inc., and as a director of Amira Pharmaceuticals, Inc., from March 2008 until its acquisition by Bristol-Myers Squibb Company in 2011. He started his career at Eli Lilly and Company in 1990 and is a chemist by training.
He holds a B.A. in chemistry from Columbia University and a Ph.D. in organic chemistry from Harvard University.